VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The promise of parsaclisib in patients with MF who have a suboptimal response to JAKi therapy

In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the benefits of combining parsaclisib with ruxolitinib as a treatment approach for patients with myelofibrosis (MF) who have a suboptimal response to JAK inhibitor monotherapy. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter